Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botensilimab + Balstilimab + Chemotherapy + Chloroquine + Celecoxib in Metastatic Pancreatic Cancer
NCT06076837Phase 1Terminated
- Sponsor
- HonorHealth Research Institute
- Start
- Jan 2025
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of botensilimab and balstilimab in pancreatic cancer (PC) (2 arms), sponsored by HonorHealth Research Institute. Primary endpoints: Maximum Tolerated Dose at 12 months and Safety and Tolerability of botensilimab in combination with balstilimab + triplet + chloroquine + celecoxib up to 2 years. Started Jan 2025; status: terminated.
02
Drugs
botensilimabbalstilimab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06076837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06076837.